Form 4: NewAmsterdam Pharma CEO Michael Davidson Acquires 5,000 Ordinary Shares

NewAmsterdam Pharma's CEO, Michael H. Davidson, recently purchased 5,000 ordinary shares of the company, increasing his direct holdings.

Summary

• On August 20, 2024, Michael H. Davidson, the CEO of NewAmsterdam Pharma Co N.V., acquired 5,000 ordinary shares of the company at a price of $16.27 per share.
• Following this transaction, Davidson directly owns 209,784 ordinary shares.
• Davidson also has indirect beneficial ownership of 608,779 ordinary shares held by Stichting Administratiekantoor EPNAP (STAK EPNAP).
• These shares are subject to forfeiture underlying depositary receipts issued by STAK EPNAP.
• STAK EPNAP has sole voting and investment power over these shares, and the depositary receipts can be cancelled by the board of directors of STAK EPNAP, potentially making Davidson the direct beneficial owner.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity. The CEO's purchase is a slightly positive signal, but not significantly impactful on its own.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis, with services like InsiderScore and OpenInsider providing data and analytics on insider trading activity.
• Comparing Davidson's transactions to those of other pharmaceutical CEOs can provide insights into the relative attractiveness of NewAmsterdam Pharma's stock.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive sign, potentially increasing investor confidence.

Key Dates